Sarah Vellotti
Family · Denison, TXNPI 1760880678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,326 and has fallen 78.3% since, to $504 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$843
- Corium, LLC$505
- Supernus Pharmaceuticals, Inc.$497
- Regeneron Healthcare Solutions, Inc.$421
- Takeda Pharmaceuticals U.S.A., Inc.$395
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,59999%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,440 |
| GSK | 44 | $843 |
| Corium, LLC | 25 | $505 |
| Supernus Pharmaceuticals, Inc. | 10 | $497 |
| Regeneron Healthcare Solutions, Inc. | 25 | $421 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $395 |
| Sanofi | 12 | $335 |
| Optinose US, Inc. | 39 | $333 |
| Mylan Specialty L.p. | 15 | $245 |
| Amgen | 11 | $207 |
| Genentech USA, Inc. | 6 | $194 |
| Sanofi-aventis U.S. LLC | 5 | $170 |
| Boehringer Ingelheim | 8 | $144 |
| AbbVie | 5 | $140 |
| Grifols USA, LLC | 6 | $106 |
| Actelion Pharmaceuticals US, Inc. | 3 | $69 |
| Tris Pharma Inc | 4 | $69 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Merck | 3 | $55 |
| Alk-abello, Inc | 1 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Biocryst US Sales Co., LLC | 1 | $43 |
| Novartis | 2 | $35 |
| Pfizer | 2 | $33 |
| Organon | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Insmed, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| Covis Pharma GmbH | 1 | $19 |
| Cranial Technologies, Inc | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Pharming Healthcare, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,699 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Other family in Denison
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.